Now that school is back in full swing and the weather is turning, flu season is creeping around the corner. This is the perfect opportunity to stock up on products to help combat the spread of the Influenza virus. According to the CDC, children younger than 18 are twice as likely to develop a symptomatic Flu virus infection than adults 65 and older. During a respiratory illness outbreak in a closed setting, like classrooms, molecular diagnostic testing determines if the influenza virus is the cause of the outbreak. 

Molecular assays identify the presence of Influenza viral RNA in respiratory specimens with high sensitivity and specificity. LaunchWorks One-Step RT-qPCR Master Mix was designed for sensitive and reproducible detection of RNA and/or DNA targets in a single or multiplexed RT-qPCR reaction. The 2X Master Mix can run multiplexed reactions including Flu A, Flu B, RSV and COVID-19. Additionally, Launchworks Viral Transport Media (VTM) and specimen collection products are designed to get your respiratory clinical sample to the diagnostic lab, without degradation. 

 

The LaunchWorks Viral Transport Media is listed per FDA guidance, “Enforcement Policy for Viral Transport Media during the Coronavirus 2019 (COVID-19) Public Health Emergency.”  LaunchWorks CDMO partners with companies to develop and optimize diagnostic products for commercial, large-scale manufacturing. LaunchWorks provides an expansive list of services, from creating custom pilot lot kits for high complexity products to fully commercialized kitting and fulfillment.  

LaunchWorks is elated to support those in the fight against the influenza virus. For more information about how LaunchWorks supports the fight against the flu, contact us here. 

 

LaunchWorks:  

  • FDA Registered 
  • ISO 13485:2016 Certified 
  • cGMP Compliant 
  • Full-Service 
  • Contract Manufacturer